27/08/2026
🚨 We waited 40 years. The "undruggable" RAS just got DRUGGED.
Yesterday, FDA approved **RASONQUE™ (daraxonrasib / RMC-6236)** — the first-ever RAS(ON) inhibitor for **pancreatic cancer**.
This is a seismic shift for the "King of Cancers."
**But here's what most people don't know: China is already ahead.** 🇨🇳
While the world celebrates RASONQUE, China has been building its own KRAS arsenal — and moving even faster into pancreatic cancer:
🔬 **3 KRAS G12C inhibitors already approved (all homegrown):**
• Fulzerasib (达伯特, Innovent) — Aug 2024
• Garsorasib (安方宁, Inventis) — Nov 2024
• Glecirasib (艾瑞凯, Jacobio) — May 2025
🔥 **HRS-4642 (恒瑞) — KRAS G12D inhibitor:**
• 63.3% response rate in first-line advanced pancreatic cancer
• Published in *Nature Medicine*
• Liposomal formulation — accumulates in tumor for 40+ days
• CDE Breakthrough Therapy Designation granted
🚀 **GFH375 (GenFleet/劲方) — KRAS G12D (ON/OFF) inhibitor:**
• China's FIRST BTD for pancreatic cancer (Feb 2026)
• Also FDA Fast Track for pancreatic cancer
• Phase III registrational trial underway — world's first
• Pioneering combo with anti-cachexia bispecific antibody
💊 **JAB-23E73 (Jacobio) — Pan-KRAS inhibitor:**
• Phase Ib/III launched in China for 1L pancreatic cancer
• ORR 38.5%, DCR 88.5% in 2L+ pancreatic cancer
• Partnership with AstraZeneca expanding globally
**China is not just catching up — in KRAS-targeted pancreatic cancer, China may already be leading.**
At JOYFUL Medical, we connect international patients with China's most advanced treatments — including clinical trials and breakthrough therapies not available anywhere else.
If you or a loved one is fighting pancreatic cancer, there are more doors to knock on than you think.
📩 [email protected]
💬 WhatsApp: +86 13721107633
🌐 www.shjoyfulmed.com
